False-positive magnetic resonance imaging prostate cancer correlates and clinical implications
- PMID: 37006206
- PMCID: PMC10062519
- DOI: 10.4103/ua.ua_22_22
False-positive magnetic resonance imaging prostate cancer correlates and clinical implications
Abstract
Background: False-positive (FP) multiparametric magnetic resonance imaging (MPMRI) obscures and swift needless biopsies in men with a high prostate-specific antigen.
Materials and methods: This was a retrospective study, in which all patients who had been exposed to consecutive MP-MRI of the prostate combined with transrectal ultrasound-guided-magnetic resonance imaging fusion-guided prostate biopsy between 2017 and 2020 were involved in the study. The FP was measured as the number of biopsies that did not encompass prostate cancer divided by the whole number of biopsies.
Results: The percentage of FP cases was 51.1%, the highest percentage was found in Prostate Imaging-Reporting and Data System (PI-RADs) 3 (37.7%) and the lowest was detected in PI-RAD 5 (14.5%). Those with FP biopsies are younger, and their total prostate antigen (PSA) and PSA density (PSAD) are significantly lesser. The area under the curve PSAD, age, and total PSA are 0.76, 0.74, and 0.69, respectively. An optimum PSAD value of 0.135 was chosen as a cutoff because it showed the highest sum of sensitivity and specificity, 68% and 69%, respectively.
Conclusion: FP results of mpMRI were detected in more than half of our sample, more than one-third were presented in Pi-RAD3, improved imaging techniques to decrease FP rates are highly needed.
Keywords: PIRADs; prostate cancer; transrectal ultrasound-guided biopsy- magnetic resonance imaging fusion-guided prostate biopsy.
Copyright: © 2022 Urology Annals.
Conflict of interest statement
There are no conflicts of interest.
Figures
Similar articles
-
How to make clinical decisions to avoid unnecessary prostate screening in biopsy-naïve men with PI-RADs v2 score ≤ 3?Int J Clin Oncol. 2020 Jan;25(1):175-186. doi: 10.1007/s10147-019-01524-9. Epub 2019 Aug 31. Int J Clin Oncol. 2020. PMID: 31473884
-
The Use of Multiparametric Magnetic Resonance Imaging for Follow-up of Patients Included in Active Surveillance Protocol. Can PSA Density Discriminate Patients at Different Risk of Reclassification?Clin Genitourin Cancer. 2020 Dec;18(6):e698-e704. doi: 10.1016/j.clgc.2020.04.006. Epub 2020 May 4. Clin Genitourin Cancer. 2020. PMID: 32493676
-
MRI combined with PSA density in detecting clinically significant prostate cancer in patients with PSA serum levels of 4∼10ng/mL: Biparametric versus multiparametric MRI.Diagn Interv Imaging. 2020 Apr;101(4):235-244. doi: 10.1016/j.diii.2020.01.014. Epub 2020 Feb 13. Diagn Interv Imaging. 2020. PMID: 32063483
-
The Value of Prostate-specific Antigen Density for Prostate Imaging-Reporting and Data System 3 Lesions on Multiparametric Magnetic Resonance Imaging: A Strategy to Avoid Unnecessary Prostate Biopsies.Eur Urol Focus. 2021 Mar;7(2):325-331. doi: 10.1016/j.euf.2019.11.012. Epub 2019 Dec 12. Eur Urol Focus. 2021. PMID: 31839564
-
Clinical utility of MR/ultrasound fusion-guided biopsy in patients with lower suspicion lesions on active surveillance for low-risk prostate cancer.Urol Oncol. 2022 Sep;40(9):407.e21-407.e27. doi: 10.1016/j.urolonc.2022.06.005. Epub 2022 Jul 8. Urol Oncol. 2022. PMID: 35811206
Cited by
-
Dynamic Contrast-Enhanced Study in the mpMRI of the Prostate-Unnecessary or Underutilised? A Narrative Review.Diagnostics (Basel). 2023 Nov 20;13(22):3488. doi: 10.3390/diagnostics13223488. Diagnostics (Basel). 2023. PMID: 37998624 Free PMC article. Review.
-
Clinical and Imaging Predictors of False-Positive and False-Negative Results in Prostate Multiparametric MRI Using PI-RADS Version 2.Radiol Imaging Cancer. 2025 Mar;7(2):e240019. doi: 10.1148/rycan.240019. Radiol Imaging Cancer. 2025. PMID: 39950963 Free PMC article.
-
Prediction of prostate biopsy outcomes at different cut-offs of prostate-specific antigen using machine learning: a multicenter study.J Egypt Natl Canc Inst. 2025 Mar 17;37(1):8. doi: 10.1186/s43046-025-00265-3. J Egypt Natl Canc Inst. 2025. PMID: 40090974
-
Toward confident prostate cancer detection using ultrasound: a multi-center study.Int J Comput Assist Radiol Surg. 2024 May;19(5):841-849. doi: 10.1007/s11548-024-03119-w. Epub 2024 May 5. Int J Comput Assist Radiol Surg. 2024. PMID: 38704793
-
Supervised contrastive loss helps uncover more robust features for photoacoustic prostate cancer identification.Front Oncol. 2025 Jul 9;15:1592815. doi: 10.3389/fonc.2025.1592815. eCollection 2025. Front Oncol. 2025. PMID: 40703547 Free PMC article.
References
-
- Abraham NE, Mendhiratta N, Taneja SS. Patterns of repeat prostate biopsy in contemporary clinical practice. J Urol. 2015;193:1178–84. - PubMed
-
- Loeb S, Vellekoop A, Ahmed HU, Catto J, Emberton M, Nam R, et al. Systematic review of complications of prostate biopsy. Eur Urol. 2013;64:876–92. - PubMed
-
- Mowatt G, Scotland G, Boachie C, Cruickshank M, Ford JA, Fraser C, et al. The diagnostic accuracy and cost-effectiveness of magnetic resonance spectroscopy and enhanced magnetic resonance imaging techniques in aiding the localisation of prostate abnormalities for biopsy: A systematic review and economic evaluation. Health Technol Assess. 2013;17 vii-xix, 1-281. - PMC - PubMed
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous